{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"33"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"33"}],"units":"Participants"}],"description":"Number of participants who experienced an adverse event while on ABT-199","groups":[{"description":"ABT199 will be administered daily, with 28 consecutive days defined as a treatment cycle for a maximum for 26 cycles\n\nABT199: Oral BCL-2 antagonist","id":"OG000","title":"ABT199"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"2 years","title":"Number of Participants With Treatment-related Adverse Events as Assessed by CTCAE v4.0","type":"SECONDARY","unitOfMeasure":"Participants"}